Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions
Keywords
Leukemia, Lymphoma, Myeloma, Dose-escalation
Brief summary
The purpose of this first in human study is to assess safety, tolerability, Pharmacokinetic (PK) and preliminary clinical activity and to estimate the Maximum Tolerated Doses (MTD(s))/ Recommended Phase 2 Doses (RP2D(s)) of S65487 as single agent administered intravenously (i.v.) in adult patients with refractory or relapsed Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) or Chronic Lymphocytic Leukemia (CLL).
Detailed description
This study is designed in two parts: one part for dose escalation, one part for dose expansion.The dose escalation part will be followed by expansion part at the MTD(s)/RP2D(s) This study will utilize an adaptative Bayesian Logistic Regression model to guide dose escalation and estimate the MTD(s) based on the Dose Limiting Toxicity (DLT) relationship(s) for S65487 in the indications.
Interventions
DRUGS65487- initial scheme
S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
DRUGS65487 - alternative scheme
S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
Sponsors
ADIR, a Servier Group company
Institut de Recherches Internationales Servier
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML, excluding acute promyelocytic leukaemia with relapsed or refractory disease without established alternative therapy. Or patients with measurable confirmed Multiple Myeloma (IMWG) with relapsed or refractory disease who have previously received at least three lines of treatment and without established alternative therapy. Or patients with histologically and measurable confirmed Non Hodgkin Lymphoma defined as Diffuse Large B cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), High-Grade B cell Lymphoma with relapsed or refractory disease who have received at least two lines of therapy (including rituximab) and without established alternative therapy. Or patients with Chronic Lymphocytic Leukemia (CLL) who have relapsed or are refractory (except treatment failure), as defined per iwCLL, from venetoclax treatment and without established alternative therapy. * ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2. * For NHL, MM patients and CLL patients: haematological function (independent of any growth factor support) based on the last assessment performed before inclusion, defined as: absolute neutrophil count (ANC) ≥ 1 x 109/L, haemoglobin ≥ 8 g/dL, platelet count ≥ 50 x 109/L for NHL and MM patients, platelet count ≥ 30 x 109/L for CLL patients. * For AML patients: circulating Blood White Cell count (WBC count) \< 25 x 109/L (with or without use of hydroxycarbamide/leukapheresis) based on the last assessment performed before inclusion. * Adequate renal function based on the last assessment performed before inclusion, assessed as Glomerular Filtration Rate (GFR) using Modification of Diet in Renal Disease (MDRD) Formula. * Adequate hepatic function based on the last assessment performed before inclusion.
Exclusion criteria
* Pregnancy, breastfeeding or possibility of becoming pregnant during the study. * Participation in another interventional study at the same time or another interventional study requiring investigational treatment intake within 3 weeks or at least 5 half-lives (whichever is longer) prior to the first S65487 administration. * Participant already enrolled in the study (informed consent signed) and has received at least one dose of S65487. * Patients who have not recovered from toxicity of previous anticancer therapy, including grade ≥ 2 non-hematologic toxicity, prior to the first IMP administration (including peripheral neurotoxicity). Certain toxicities will not be considered in this category (e.g. alopecia). * Patients refractory to a previous treatment with a Bcl-2 inhibitor. * For AML patients : Allogenic stem cell transplant within 3 months before the first IMP administration and/or patients who still receive immunosuppressive treatment within 3 months before the first IMP administration and/or patients with active Graft-versus-host disease within 3 months before the first IMP administration and/or patient who receive donor lymphocyte infusion (DLI) within 3 months before the first IMP administration. * For NHL, MM and CLL patients : Prior allogenic stem cell transplant before the first IMP administration and/or Autologous stem cell transplant within 3 months before the first IMP administration.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose intensity | through study completion an average of 6 months | — |
| Incidence of Dose Limiting Toxicity (DLT) | until the end of the first cycle (each cycle is 21days) | Safety criterion |
| Incidence and severity of Adverse Events | through study completion an average of 6 months | Safety and tolerability criteria |
| Incidence and severity of Serious Adverse Events | through study completion an average of 6 months | Safety and tolerability criteria |
| Number of participants with dose reductions | through study completion an average of 6 months | — |
| Number of participants with dose interruptions | through study completion an average of 6 months | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The pharmacokinetic (PK) profile of S65487: Area Under the Curve (AUC) | Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3 (alternative schedule only), Cyle 1 Day 5 (alternative schedule only), Cycle 1 Day 8, Cycle 1 Day 9, Day 1 of next cycles (one cycle is 21 days) | — |
| PK profile of S65487: Volume of distribution at steady-state (Vss) | Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3 (alternative schedule only), Cyle 1 Day 5 (alternative schedule only), Cycle 1 Day 8, Cycle 1 Day 9, Day 1 of next cycles (one cycle is 21 days) | — |
| PK profile of S65487: total CLearance (CL) | Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3 (alternative schedule only), Cyle 1 Day 5 (alternative schedule only), Cycle 1 Day 8, Cycle 1 Day 9, Day 1 of next cycles (one cycle is 21 days) | — |
| PK profile of S65487: terminal half-life (t½z) | Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3 (alternative schedule only), Cyle 1 Day 5 (alternative schedule only), Cycle 1 Day 8, Cycle 1 Day 9, Day 1 of next cycles (one cycle is 21 days) | — |
| Best Overall Response (BOR) | Through study completion, an average of 6 months | Best Response observed during the treatment period |
| Overall Response Rate (ORR) | Through study completion, an average of 6 months | Proportion of patients in whom a complete response (CR) or a partial response (PR) |
Countries
Australia, France, Spain, United Kingdom
Outcome results
None listed